13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001844645
Total reported value
$307.8M
$307.8M
12 檔
46.2%
During the Q2 2025 filing period, Pivotal bioVenture Partners Investment Advisor LLC (CIK: 0001844645) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $307.8M across 12 reported positions.
During Q2 2025, Pivotal bioVenture Partners Investment Advisor LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCS | Oculis Holding AG | Stock-Other | 27.68% | -9.18% | — | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 26.30% | -1.59% | +83.63% | |
| 3 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 18.43% | -0.64% | — | |
| 4 | ✓ | Inozyme Pharma Inc | Stock-Other | 11.14% | — | — | |
| 5 | ZBIO | Zenas Biopharma Inc | Stock-Other | 4.68% | -0.09% | +5.76% | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.89% | +3.93% | — | |
| 7 | VIGL | Vigil Neuroscience Inc | Stock-Other | 2.76% | — | — | |
| 8 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 1.87% | +0.06% | — | |
| 9 | BIOA | Bioage Labs Inc | Stock-Other | 1.67% | +1.12% | — | |
| 10 | IOBTQ | Io Biotech Inc | Stock-Other | 0.74% | — | — | |
| 11 | ✓ | Rallybio CORP | Stock-Other | 0.50% | — | — | |
| 12 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.34% | -0.06% | EXIT |
According to official SEC Form 13F filings, Pivotal bioVenture Partners Investment Advisor LLC reported a total U.S. public equity portfolio value of $307.8M across 12 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCS, PCVX, ARQT) accounted for 46.2% of total reported equity market value during Q2 2025.
During Q2 2025, Pivotal bioVenture Partners Investment Advisor LLC's top holdings by market value included OCS (27.7%)、PCVX (26.3%)、ARQT (18.4%). The largest single position, OCS, represented 27.7% of total portfolio value.
In Q2 2025, Pivotal bioVenture Partners Investment Advisor LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.